Claims for Patent: 6,346,398

Summary for Patent: 6,346,398

Title:	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
Abstract:	Nucleic acid molecule which modulates the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor.
Inventor(s):	Pavco; Pamela (Lafayette, CO), McSwiggen; James (Boulder, CO), Stinchcomb; Daniel (Boulder, CO), Escobedo; Jaime (Alamo, CA)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	08/584,040
Patent Claims:	1. A nucleic acid molecule which specifically inhibits the synthesis, expression and/or stability of an mRNA encoding flt-1 receptor of human or mouse vascular endothelial growth factor, wherein said nucleic acid molecule is an enzymatic nucleic acid molecule or an antisense nucleic acid molecule. 2. The nucleic acid of claim 1, wherein said nucleic acid molecule is an enzymatic nucleic acid molecule. 3. The nucleic acid molecule of claim 2, wherein said enzymatic nucleic acid molecule comprises binding arms containing sequence complementary to a substrate nucleotide base sequence to any one of SEQ ID NOS; 1481-1482, 1493, 1574, 1664, 1669, 1838, 1847, 1913, 1933, 1974, 1984, 1997, 1999, 2000, 2025, 2130, 2382, or 2394. 4. The nucleic acid molecule of claims 2, wherein said nucleic acid molecule is in a hammerhead motif. 5. The nucleic acid molecule of claim 2, wherein said nucleic acid molecule is in a hairpin, hepatitis Delta virus, group I intron, VS nucleic acid or RNase P nucleic acid motif. 6. A method of cleaving RNA of flt-1 gene comprising the step of contacting said RNA with the enzymatic nucleic acid molecule of claim 3, under conditions suitable for the cleavage of said RNA. 7. The method claim 6, wherein said enzymatic nucleic acid molecule is in a hammerhead motif. 8. The method of claim 6, wherein said enzymatic nucleic acid molecule comprises between 12 and 100 bases complementary to the RNA of flt-1 gene. 9. The method of claim 6, wherein said enzymatic nucleic acid molecule comprises between 14 and 24 bases complementary to the RNA of flt-1 gene. 10. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises between 12 and 100 bases complementary to the RNA encoding the flt-1 receptor. 11. The nucleic acid molecule of claim 10, wherein said nucleic acid molecule comprises between 14 and 24 bases complementary to the RNA encoding the flt-1 receptor. 12. A mammalian cell including a nucleic acid molecule of claim 1, wherein said mammalian cell is not a living human. 13. The mammalian cell of claim 12, wherein said mammalian cell is a human cell. 14. An expression vector comprising nucleic acid sequence encoding the nucleic acid molecule of claim 1, in a manner which allows expression and/or delivery of that nucleic acid molecule within a mammalian cell. 15. The expression vector of claim 14, wherein said nucleic acid molecule is an enzymatic nucleic acid. 16. A mammalian cell including an expression vector of claim 11, wherein said mammalian cell is not a living human. 17. The mammalian cell of claim 16, wherein said mammalian cell is a human cell. 18. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is an antisense nucleic acid molecule. 19. The nucleic acid molecule of claim 18, wherein said antisense nucleic acid molecule contains sequence complementary to the substrate nucleotide base sequence selected from the group consisting of: 1481-1482, 1493, 1574, 1664, 1669, 1838, 1847, 1913, 1933, 1974, 1984, 1997, 1999, 2000, 2025, 2130, 2382, or 2394. 20. An expression vector comprising nucleic acid sequence encoding the antisense nucleic acid molecule of claim 18, in a manner which allows expression and/or delivery of that antisense nucleic acid molecule within a mammalian cell. 21. A mammalian cell including the expression vector of claim 20, wherein said mammalian cell is not a living human. 22. The mammalian cell of claim 21, wherein said mammalian cell is a human cell. 23. An enzymatic nucleic acid molecule comprising any ribozyme sequence selected from the group consisting of: SEQ ID NOS: 50-51, 62, 143, 233, 238, 407, 416-417, 482, 502, 543, 553, 566, 568-569, 574, 594, 699, 951, and 963.

Details for Patent 6,346,398

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-10-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-10-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-10-26